NCT04032717 (PREVENT) is a Phase 1 clinical trial of Q-Griffithsin (Q-GRFT) enema in HIV Prevention, sponsored by Rhonda Brand.

Who is sponsoring NCT04032717?

NCT04032717 is sponsored by Rhonda Brand.

What drugs are being tested in NCT04032717?

Interventions in NCT04032717: Q-Griffithsin (Q-GRFT) enema, Placebo enema.

What condition does NCT04032717 study?

NCT04032717 studies HIV Prevention.

Is NCT04032717 still recruiting?

NCT04032717 is currently terminated. Last updated 6 July 2023.

Last reviewed 2023-07-06 · How we verify

NCT04032717: PREVENT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Griffithsin-based Rectal Microbicide for PREvention of Viral ENTry (PREVENT)

Terminated Phase 1 Last updated 6 July 2023

What this trial tests

Phase 1 trial testing Q-Griffithsin (Q-GRFT) enema in HIV Prevention in 18 participants. Terminated before completion.

Timeline

10 July 2019

Primary endpoint
4 February 2021

4 February 2021

Quick facts

Lead sponsor	Rhonda Brand
Phase	Phase 1
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	prevention
Enrollment	18
Start date	10 July 2019
Primary completion	4 February 2021
Estimated completion	4 February 2021
Sites	1 location across United States

Drugs / interventions tested

Q-Griffithsin (Q-GRFT) enema — full drug profile →
Placebo enema

Conditions studied

HIV Prevention — all drugs for HIV Prevention →

Sponsor

Rhonda Brand — full company profile →

Who can join

Adults 18 to 45, any sex, with HIV Prevention. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is the first-in-human clinical study to see if a single dose of an investigational enema made from a modified plant protein called Q-Griffithsin is safe, tolerated, and acceptable for use by healthy adults 18-45 years of age who practice receptive anal intercourse.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Phytopharmaceuticals mediated Furin and TMPRSS2 receptor blocking: can it be a potential therapeutic option for Covid-19?
Palit P, Chattopadhyay D, Thomas S, Kundu A, et al · · 2021 · cited 20× · PMID 33380375 · DOI 10.1016/j.phymed.2020.153396
Novel Antifungal Activity of Q-Griffithsin, a Broad-Spectrum Antiviral Lectin.
Nabeta HW, Kouokam JC, Lasnik AB, Fuqua JL, et al · · 2021 · cited 14× · PMID 34494857 · DOI 10.1128/spectrum.00957-21
An algal lectin griffithsin inhibits Hantaan virus infection in vitro and in vivo.
Zhao Y, Zhao N, Cai Y, Zhang H, et al · · 2022 · cited 10× · PMID 36579342 · DOI 10.3389/fcimb.2022.881083
Women for science and science for women: Gaps, challenges and opportunities towards optimizing pre-exposure prophylaxis for HIV-1 prevention.
Karim QA, Archary D, Barré-Sinoussi F, Broliden K, et al · · 2022 · cited 10× · PMID 36561760 · DOI 10.3389/fimmu.2022.1055042
HIV-1 Entry and Prospects for Protecting against Infection.
Bruxelle JF, Trattnig N, Mureithi MW, Landais E, et al · · 2021 · cited 10× · PMID 33499233 · DOI 10.3390/microorganisms9020228
In vitro Inhibition of HIV-1 by Cyclotide-Enriched Extracts of Viola tricolor.
Conzelmann C, Muratspahić E, Tomašević N, Münch J, et al · · 2022 · cited 9× · PMID 35712712 · DOI 10.3389/fphar.2022.888961
Hantavirus Infection Is Inhibited by Griffithsin in Cell Culture.
Shrivastava-Ranjan P, Lo MK, Chatterjee P, Flint M, et al · · 2020 · cited 9× · PMID 33251157 · DOI 10.3389/fcimb.2020.561502
The Need for Ocular Protection for Health Care Workers During SARS-CoV-2 Outbreak and a Hypothesis for a Potential Personal Protective Equipment.
Wang L, Deng Y. · · 2020 · cited 6× · PMID 33282819 · DOI 10.3389/fpubh.2020.599757

Verify or expand the search:

Other recruiting trials for HIV Prevention

Currently open trials in the same condition.

NCT07194902 — HIV Self-testing for Partners of HIV-uninfected Postpartum Women · NA · recruiting
NCT07218211 — Enhancing PrEP Uptake and Retention Among Latine TGW and GBM in the South Using Long-Acting Injectable PrEP · Phase 4 · recruiting
NCT07349758 — Evaluation of Single Dosing With Two F/TAF Tablets Among Healthy Volunteers · Phase 1 · recruiting
NCT07433985 — California MEPS Hub · NA · recruiting
NCT07002866 — Suubi4PrEP: Improving PrEP Access and Adherence Among Adolescent Girls and Young Women in Uganda · NA · recruiting

Other Rhonda Brand trials

Trials by the same sponsor.

NCT04302896 — Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs · EARLY_PHASE1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04032717 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Rhonda Brand
Last refreshed: 6 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04032717.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing